Serotypes | Periods | Total | ||||||
---|---|---|---|---|---|---|---|---|
1998–2002 | 2003–2010 | 2011–2013 | ||||||
no | %* | no | %* | no | %* | no | % | |
PCV7 | ||||||||
14 | 45 | 20.3 | 94 | 19.6 | 6 | 6.3 | 145 | 18.2 |
19F | 15 | 6.8 | 28 | 5.8 | 3 | 3.2 | 46 | 5.8 |
6B | 7 | 3.2 | 27 | 5.6 | 4 | 4.2 | 38 | 4.8 |
23F | 8 | 3.6 | 29 | 6.1 | 0 | 0.0 | 37 | 4.6 |
9V | 6 | 2.7 | 25 | 5.2 | 3 | 3.2 | 34 | 4.3 |
18C | 13 | 5.9 | 15 | 3.1 | 5 | 5.3 | 33 | 4.1 |
4 | 8 | 3.6 | 13 | 2.7 | 3 | 3.2 | 24 | 3.0 |
Total PCV7 | 102 | 45.9 | 231 | 48.2 | 24 | 25.3 | 357 | 44.8 |
Included PCV10 | ||||||||
1 | 12 | 5.4 | 31 | 6.5 | 0 | 0.0 | 43 | 5.4 |
7 F | 7 | 3.2 | 12 | 2.5 | 2 | 2.1 | 21 | 2.6 |
5 | 14 | 6.3 | 1 | 0.2 | 2 | 2.1 | 17 | 2.1 |
Total PCV10 | 33 | 14.9 | 44 | 9.2 | 4 | 4.2 | 81 | 10.2 |
Included PCV13 | ||||||||
3 | 14 | 6.3 | 42 | 8.8 | 17 | 17.9 | 73 | 9.2 |
6A | 13 | 5.9 | 20 | 4.2 | 6 | 6.3 | 39 | 4.9 |
19A | 13 | 5.9 | 18 | 3.8 | 2 | 2.1 | 33 | 4.1 |
Total PCV13 | 40 | 18.0 | 80 | 16.7 | 25 | 26.3 | 145 | 18.2 |
Non-vaccine | ||||||||
12F | 1 | 0.5 | 18 | 3.8 | 9 | 9.5 | 28 | 3.5 |
11A | 0 | 0.0 | 12 | 2.5 | 3 | 3.2 | 15 | 1.9 |
22F | 3 | 1.4 | 12 | 2.5 | 0 | 0.0 | 15 | 1.9 |
8 | 2 | 0.9 | 5 | 1.0 | 5 | 5.3 | 12 | 1.5 |
9N | 1 | 0.5 | 6 | 1.3 | 3 | 3.2 | 10 | 1.3 |
10A | 3 | 1.4 | 5 | 1.0 | 1 | 1.1 | 9 | 1.1 |
15C | 2 | 0.9 | 3 | 0.6 | 4 | 4.2 | 9 | 1.1 |
17F | 3 | 1.4 | 5 | 1.0 | 0 | 0.0 | 8 | 1.0 |
6C | 1 | 0.5 | 3 | 0.6 | 4 | 4.2 | 8 | 1.0 |
18A | 4 | 1.8 | 3 | 0.6 | 0 | 0.0 | 7 | 0.9 |
18B | 2 | 0.9 | 5 | 1.0 | 0 | 0.0 | 7 | 0.9 |
23B | 1 | 0.5 | 5 | 1.0 | 0 | 0.0 | 6 | 0.8 |
NT | 3 | 1.4 | 3 | 0.6 | 0 | 0.0 | 6 | 0.8 |
NR | 0 | 0.0 | 2 | 0.4 | 0 | 0.0 | 2 | 0.3 |
Othera | 21 | 9.5 | 37 | 7.7 | 13 | 13.7 | 71 | 8.9 |
Total non- vaccine | 47 | 21.2 | 124 | 25.9 | 42 | 44.2 | 215 | 27.0 |
Total | 222 | 100.0 | 479 | 100.0 | 95 | 100.0 | 796 | 100.0 |